-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would reimburse patients for the cost of Alzheimer's treatments that target an abnormal protein called beta amyloid.
The Centers for Medicare and Medicaid Services said it would pay for fully approved anti-amyloid drugs for patients with a formal diagnosis enrolled in a patient registry. The news puts Biogen and Eisai's Leqembi on track for full reimbursement. Leqembi is an amyloid-targeting Alzheimer's treatment that won accelerated approval in January.
Importantly, the CMS policy extends to all drugs in the anti-amyloid class. That also includes Eli Lilly's drug, donanemab, which is also being tested in Alzheimer's treatment.
"CMS previously hinted that full approval would open the door for reimbursement, so that decision would seem as anticipated," Wedbush analyst Laura Chico said in a note to clients. "We think there was more debate on the potential for a registry."
In morning trades on today's stock market, Biogen stock surged 2.7% near 304.40. Eisai stock jumped 3.7% near 16.40. Meanwhile, Lilly shares advanced 1% near 433.80.
Biogen Stock: Patient Registry Is A Challenge
The registry requirement was a sticking point with the Alzheimer's Association. The association called the requirement "an unnecessary burden." Wedbush's Chico noted patients would have to find a physician willing to participate in a patient registry.
"Registries are important tools to gather much needed real-world evidence to transform and improve patient care," the Alzheimer's Association said in a written statement. "But registries should not be a requirement for coverage of an FDA-approved treatment."
Still, Biogen stock pushed back into a 5% chase zone above a buy point at 296 out of a double-bottom base, according to MarketSmith.com. The company's first Alzheimer's treatment, Aduhelm, also gained accelerated approval. But CMS said it wouldn't pay for Aduhelm unless patients were enrolled in Biogen's confirmatory study. That was such a barrier that Biogen unwound its Aduhelm efforts.
Chico kept her neutral rating and 263 price target on Biogen shares.
"Logistical rollout of the drug is another issue to contend with, and we do not anticipate a rapid launch uptake curve will manifest as the registries get sorted out," he said.
Biogen stock is highly rated with an IBD Digital Relative Strength Rating of 93. This puts shares in the top 7% of all stocks when it comes to 12-month performance.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Arrowhead CEO Christopher Anzalone Addresses This 'Really Important Event' In Lung Disease
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
Join IBD Live For Stock Ideas Each Morning Before The Open
Options Trading: How To Start Using Options, How To Manage Risk
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would reimburse patients for the cost of Alzheimer's treatments that target an abnormal protein called beta amyloid.
Bioge 週四,在醫療保險官員表示將向患者報銷針對一種叫做β澱粉樣蛋白的異常蛋白質的阿爾茨海默氏症治療費用後,股價週四跳入買入區。
The Centers for Medicare and Medicaid Services said it would pay for fully approved anti-amyloid drugs for patients with a formal diagnosis enrolled in a patient registry. The news puts Biogen and Eisai's Leqembi on track for full reimbursement. Leqembi is an amyloid-targeting Alzheimer's treatment that won accelerated approval in January.
醫療保險和醫療補助服務中心表示,它將爲在患者登記處登記的有正式診斷的患者支付獲得全面批准的抗澱粉樣蛋白藥物的費用。消息說,Biogen 和 衛材的Leqembi有望獲得全額報銷。Leqembi是一種針對澱粉樣蛋白的阿爾茨海默氏症治療藥物,在1月份獲得了加速批准。
Importantly, the CMS policy extends to all drugs in the anti-amyloid class. That also includes Eli Lilly's drug, donanemab, which is also being tested in Alzheimer's treatment.
重要的是,CMS政策適用於抗澱粉樣蛋白類的所有藥物。這還包括 Eli Lilly的藥物 donanemab 也正在阿爾茨海默氏症的治療中進行測試。
"CMS previously hinted that full approval would open the door for reimbursement, so that decision would seem as anticipated," Wedbush analyst Laura Chico said in a note to clients. "We think there was more debate on the potential for a registry."
Wedbush分析師勞拉·奇科在給客戶的報告中表示:“CMS此前曾暗示,全面批准將爲報銷打開大門,因此這一決定似乎如預期的那樣。”“我們認爲,關於註冊的可能性還有更多爭論。”
In morning trades on today's stock market, Biogen stock surged 2.7% near 304.40. Eisai stock jumped 3.7% near 16.40. Meanwhile, Lilly shares advanced 1% near 433.80.
在今天股市的早盤交易中,Biogen股價飆升2.7%,接近304.40。衛材股價上漲3.7%,接近16.40。同時,禮來公司股價上漲了1%,接近433.80。
Biogen Stock: Patient Registry Is A Challenge
Biogen Stock:患者登記是一項挑戰
The registry requirement was a sticking point with the Alzheimer's Association. The association called the requirement "an unnecessary burden." Wedbush's Chico noted patients would have to find a physician willing to participate in a patient registry.
註冊要求是阿爾茨海默氏症協會的癥結所在。該協會稱該要求是 “不必要的負擔”。Wedbush的奇科指出,患者必須找到願意參與患者登記的醫生。
"Registries are important tools to gather much needed real-world evidence to transform and improve patient care," the Alzheimer's Association said in a written statement. "But registries should not be a requirement for coverage of an FDA-approved treatment."
阿爾茨海默氏症協會在一份書面聲明中說:“登記是收集急需的現實世界證據以改變和改善患者護理的重要工具。”“但是,註冊不應成爲美國食品藥品管理局批准的治療的承保範圍的要求。”
Still, Biogen stock pushed back into a 5% chase zone above a buy point at 296 out of a double-bottom base, according to MarketSmith.com. The company's first Alzheimer's treatment, Aduhelm, also gained accelerated approval. But CMS said it wouldn't pay for Aduhelm unless patients were enrolled in Biogen's confirmatory study. That was such a barrier that Biogen unwound its Aduhelm efforts.
根據MarketsMith.com的數據,儘管如此,Biogen的股票仍從雙底基礎上回到了5%的追漲區間,高於買入點296點。該公司的首個阿爾茨海默氏症治療藥物Aduhelm也獲得了加速批准。但CMS表示,除非患者參加Biogen的確認性研究,否則它不會爲Aduhelm付費。這是一道屏障,以至於Biogen解除了阿杜海姆的努力。
Chico kept her neutral rating and 263 price target on Biogen shares.
奇科維持了對Biogen股票的中性評級和263的目標股價。
"Logistical rollout of the drug is another issue to contend with, and we do not anticipate a rapid launch uptake curve will manifest as the registries get sorted out," he said.
他說:“該藥物的物流推廣是另一個需要解決的問題,我們預計隨着登記冊的整理,不會出現快速的上市使用曲線。”
Biogen stock is highly rated with an IBD Digital Relative Strength Rating of 93. This puts shares in the top 7% of all stocks when it comes to 12-month performance.
Biogen股票獲得了很高的評級,IBD數字相對強度評級爲93。就12個月的表現而言,這使得股票在所有股票中名列前7%。
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
在 Twitter 上關注艾莉森·加特林,網址爲 @IBD_AGatlin。
YOU MAY ALSO LIKE:
你可能還喜歡:
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Biohaven 如何 “退出隱身模式” ——並瘋狂地延長了爲期 4 天的運行時間
Arrowhead CEO Christopher Anzalone Addresses This 'Really Important Event' In Lung Disease
Arrowhead 首席執行官克里斯托弗·安扎隆在肺部疾病中談到了這個 “非常重要的事件”
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
如何研究成長型股票:爲甚麼這個IBD工具簡化了對熱門股票的搜索
Join IBD Live For Stock Ideas Each Morning Before The Open
每天早上開盤前加入 IBD Live 獲取股票創意
Options Trading: How To Start Using Options, How To Manage Risk
期權交易:如何開始使用期權,如何管理風險
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧